Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: A multicenter real-world study in the northwest of China

Real-world data of Palbociclib are insufficient in China. This study aimed to investigate the treatment pattern and real-world outcomes in hormone receptor positive and human epidermal growth factor 2 receptor negative (HR+/HER2-) metastatic breast cancer (MBC) patients treated with Palbociclib in the northwest of China.